$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
服用特罗凯耐药后怎么办?
2025-10-19 11:44:20
Check Details
服用易瑞沙出现胃肠道不适怎么办?
2025-10-19 11:44:20
Check Details
舒尼替尼治疗肺癌安全耐受
2025-10-19 11:44:20
Check Details
阿法替尼延长EGFR敏感突变肺癌患者无进展生存时间
2025-10-19 11:44:20
Check Details
阿法替尼治疗晚期肺鳞癌
2025-10-19 11:44:20
Check Details
舒尼替尼与化疗联合治疗NSCLC患者安全耐受
2025-10-19 11:44:20
Check Details
易瑞沙可用于晚期化疗失败的肺癌患者
2025-10-19 11:44:20
Check Details
特罗凯治疗肺鳞癌效果优于化疗
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK阳性NSCLC疗效优于化疗
2025-10-19 11:44:20
Check Details
肺癌患者服用舒尼替尼常见的不良反应
2025-10-19 11:44:20
Check Details
克唑替尼使ROS1阳性NSCLC获益
2025-10-19 11:44:20
Check Details
奥希替尼治疗EGFR突变阳性的NSCLC有效率高达80%
2025-10-19 11:44:20
Check Details
1
2
...
2996
2997
2998
2999
3000
3001
3002
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
3
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
4
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
5
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
6
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
7
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
8
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
9
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor